Therapeutic strategies for COVID-19: progress and lessons learned
G Li, R Hilgenfeld, R Whitley, E De Clercq - Nature Reviews Drug …, 2023 - nature.com
Abstract The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …
The T cell immune response against SARS-CoV-2
P Moss - Nature immunology, 2022 - nature.com
The adaptive immune response is a major determinant of the clinical outcome after SARS-
CoV-2 infection and underpins vaccine efficacy. T cell responses develop early and …
CoV-2 infection and underpins vaccine efficacy. T cell responses develop early and …
Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo …
Background Baricitinib is an oral selective Janus kinase 1/2 inhibitor with known anti-
inflammatory properties. This study evaluates the efficacy and safety of baricitinib in …
inflammatory properties. This study evaluates the efficacy and safety of baricitinib in …
Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial
Early increase of soluble urokinase plasminogen activator receptor (suPAR) serum levels is
indicative of increased risk of progression of coronavirus disease 2019 (COVID-19) to …
indicative of increased risk of progression of coronavirus disease 2019 (COVID-19) to …
Effect of noninvasive respiratory strategies on intubation or mortality among patients with acute hypoxemic respiratory failure and COVID-19: the RECOVERY-RS …
Importance Continuous positive airway pressure (CPAP) and high-flow nasal oxygen
(HFNO) have been recommended for acute hypoxemic respiratory failure in patients with …
(HFNO) have been recommended for acute hypoxemic respiratory failure in patients with …
Therapeutics for COVID-19
SS Toussi, JL Hammond, BS Gerstenberger… - Nature …, 2023 - nature.com
Vaccines and monoclonal antibody treatments to prevent severe coronavirus disease 2019
(COVID-19) illness were available within a year of the pandemic being declared but there …
(COVID-19) illness were available within a year of the pandemic being declared but there …
Pathophysiology of COVID-19-associated acute kidney injury
Although respiratory failure and hypoxaemia are the main manifestations of COVID-19,
kidney involvement is also common. Available evidence supports a number of potential …
kidney involvement is also common. Available evidence supports a number of potential …
[HTML][HTML] Neutralizing monoclonal antibodies for treatment of COVID-19
PC Taylor, AC Adams, MM Hufford… - Nature Reviews …, 2021 - nature.com
Several neutralizing monoclonal antibodies (mAbs) to severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) have been developed and are now under evaluation in clinical …
coronavirus 2 (SARS-CoV-2) have been developed and are now under evaluation in clinical …
COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations
The COVID-19 pandemic has brought challenges for people with rheumatic disease in
addition to those faced by the general population, including concerns about higher risks of …
addition to those faced by the general population, including concerns about higher risks of …
Effect of 12 mg vs 6 mg of dexamethasone on the number of days alive without life support in adults with COVID-19 and severe hypoxemia: the COVID STEROID 2 …
L Russell, KR Uhre, ALS Lindgaard, JF Degn… - Jama, 2021 - jamanetwork.com
Importance A daily dose with 6 mg of dexamethasone is recommended for up to 10 days in
patients with severe and critical COVID-19, but a higher dose may benefit those with more …
patients with severe and critical COVID-19, but a higher dose may benefit those with more …